273 related articles for article (PubMed ID: 36809835)
1. New Treatment Paradigms in Primary Biliary Cholangitis.
Levy C; Manns M; Hirschfield G
Clin Gastroenterol Hepatol; 2023 Jul; 21(8):2076-2087. PubMed ID: 36809835
[TBL] [Abstract][Full Text] [Related]
2. Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis.
Kremer AE; Mayo MJ; Hirschfield G; Levy C; Bowlus CL; Jones DE; Steinberg A; McWherter CA; Choi YJ
Liver Int; 2022 Jan; 42(1):112-123. PubMed ID: 34403559
[TBL] [Abstract][Full Text] [Related]
3. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
de Vries E; Bolier R; Goet J; Parés A; Verbeek J; de Vree M; Drenth J; van Erpecum K; van Nieuwkerk K; van der Heide F; Mostafavi N; Helder J; Ponsioen C; Oude Elferink R; van Buuren H; Beuers U;
Gastroenterology; 2021 Feb; 160(3):734-743.e6. PubMed ID: 33031833
[TBL] [Abstract][Full Text] [Related]
4. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
Mayo MJ
Hepatology; 2022 Aug; 76(2):518-531. PubMed ID: 35152430
[TBL] [Abstract][Full Text] [Related]
6. [Primary biliary cholangitis].
Soret PA; Chazouillères O; Corpechot C
Rev Prat; 2021 Oct; 71(8):885-891. PubMed ID: 35147347
[TBL] [Abstract][Full Text] [Related]
7. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
Hirschfield GM; Dyson JK; Alexander GJM; Chapman MH; Collier J; Hübscher S; Patanwala I; Pereira SP; Thain C; Thorburn D; Tiniakos D; Walmsley M; Webster G; Jones DEJ
Gut; 2018 Sep; 67(9):1568-1594. PubMed ID: 29593060
[TBL] [Abstract][Full Text] [Related]
8. What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
Wong LL; Hegade VS; Jones DEJ
Dig Dis; 2017; 35(4):359-366. PubMed ID: 28468009
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.
Wang C; Shi Y; Wang X; Ma H; Liu Q; Gao Y; Niu J
Front Immunol; 2022; 13():940688. PubMed ID: 35880178
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis and Treatment of Primary Biliary Cholangitis].
Kim KA
Korean J Gastroenterol; 2023 Feb; 81(2):86-90. PubMed ID: 36824036
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kowdley KV; Bowlus CL; Levy C; Akarca US; Alvares-da-Silva MR; Andreone P; Arrese M; Corpechot C; Francque SM; Heneghan MA; Invernizzi P; Jones D; Kruger FC; Lawitz E; Mayo MJ; Shiffman ML; Swain MG; Valera JM; Vargas V; Vierling JM; Villamil A; Addy C; Dietrich J; Germain JM; Mazain S; Rafailovic D; Taddé B; Miller B; Shu J; Zein CO; Schattenberg JM; ;
N Engl J Med; 2024 Feb; 390(9):795-805. PubMed ID: 37962077
[TBL] [Abstract][Full Text] [Related]
12. PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales.
Colapietro F; Gershwin ME; Lleo A
J Transl Autoimmun; 2023; 6():100188. PubMed ID: 36684809
[TBL] [Abstract][Full Text] [Related]
13. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
[TBL] [Abstract][Full Text] [Related]
14. Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases
Nevens F; Trauner M; Manns MP
J Hepatol; 2023 Feb; 78(2):430-441. PubMed ID: 36272496
[TBL] [Abstract][Full Text] [Related]
15. Primary biliary cholangitis.
Lleo A; Wang GQ; Gershwin ME; Hirschfield GM
Lancet; 2020 Dec; 396(10266):1915-1926. PubMed ID: 33308474
[TBL] [Abstract][Full Text] [Related]
16. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
Bowlus CL; Galambos MR; Aspinall RJ; Hirschfield GM; Jones DEJ; Dörffel Y; Gordon SC; Harrison SA; Kremer AE; Mayo MJ; Thuluvath PJ; Levy C; Swain MG; Neff GW; Sheridan DA; Stanca CM; Berg CP; Goel A; Shiffman ML; Vierling JM; Boudes P; Steinberg A; Choi YJ; McWherter CA
J Hepatol; 2022 Aug; 77(2):353-364. PubMed ID: 35367282
[TBL] [Abstract][Full Text] [Related]
17. Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends.
Gao L; Wang L; Woo E; He X; Yang G; Bowlus C; Leung PSC; Gershwin ME
Clin Rev Allergy Immunol; 2020 Oct; 59(2):175-194. PubMed ID: 31713023
[TBL] [Abstract][Full Text] [Related]
18. Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives.
Barba Bernal R; Ferrigno B; Medina Morales E; Castro CM; Goyes D; Trivedi H; Patwardhan VR; Bonder A
Turk J Gastroenterol; 2023 Feb; 34(2):89-100. PubMed ID: 36843300
[TBL] [Abstract][Full Text] [Related]
19. Relationship between pruritus and sleep in participants with primary biliary cholangitis in the Phase 2b GLIMMER trial.
von Maltzahn R; Mayo MJ; Smith HT; Thompson A; Das S; de Souza AR; Lisi E; Levy C; McLaughlin MM; Jones D
J Patient Rep Outcomes; 2024 Jun; 8(1):60. PubMed ID: 38862718
[TBL] [Abstract][Full Text] [Related]
20. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
